权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mechanism of estrogen independent proliferation in ER+ breast cancer cells

ER乳腺癌细胞雌激素非依赖性增殖机制

基本信息

批准号：
10737869
负责人：
Aritro Nath
金额：
$ 9.15万
依托单位：
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-01 至 2026-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10737869
关键词：
Acceleration Automobile Driving Biological Models Biopsy Breast Cancer Cell Breast Cancer Patient Bypass CDK4 gene Cancer Control Cancer Patient Cell Cycle Cell Cycle Checkpoint Cell Cycle Progression Cell Cycle Regulation Cell Line Cell Lineage Cell Proliferation Cell division Cells Cessation of life Chemosensitization Clinical Clinical Trials Collection Combined Modality Therapy Couples Cyclin-Dependent Kinase Inhibitor Data Dose Drug Combinations Drug Modelings Drug usage ERBB2 gene Effectiveness Endocrine Equilibrium ErbB4 gene Estrogen receptor positive Estrogens Evolution Feedback Gene Expression Gene Expression Profile Hand In Vitro Letrozole MAP Kinase Gene Maps Measurement Measures Mediating Mitogen-Activated Protein Kinase Kinases Modeling Outcome Study Pathway interactions Patients Pharmaceutical Preparations Pharmacotherapy Phosphotransferases Population Preoperative Endocrine Therapy Proliferating Repression Resistance Role Sampling Series Signal Pathway Signal Transduction System Testing Therapeutic Time Tumor stage Up-Regulation cancer cell cell type design drug testing experimental study hormone therapy improved outcome in vitro Model in vivo inhibitor kinase inhibitor malignant breast neoplasm mathematical model neoplastic cell patient response personalized medicine prevent promoter reconstruction refractory cancer resistance mechanism response single-cell RNA sequencing targeted treatment therapy resistant tool transcriptomics treatment strategy tumor tumor heterogeneity

项目摘要

Abstract Combining cyclin-dependent kinase (CDK) inhibitors with endocrine therapy improves outcomes for metastatic estrogen receptor positive (ER+), HER2 negative, breast cancer patients. However, the value of this combination in potentially curable earlier stage patients is variable. Our preliminary results examined the evolutionary trajectories of early stage breast cancer tumors using single cell transcriptomic profiling of serial tumor biopsies from a clinical trial of preoperative endocrine therapy alone (letrozole) or in combination with the cell cycle inhibitor ribociclib. Resistant tumors with accelerated loss of estrogen signaling show up-regulation of the JNK pathway, while those that maintain estrogen signaling during therapy show potentiation of CDK4/6 activation consistent with ERBB4 and ERK signaling up-regulation. Cell cycle reconstruction identified that tumors cells can reactivate during combination treatment, indicating stronger selection for a proliferative state. We hypothesize that resistance to CDK4/6 inhibition in earlier stage breast cancer is driven by JNK MAPK pathway stimulation and reactivation of the cell cycle through promotion of CDK6 expression or decreased cell cycle inhibitor function. In Aim 1, we will use a new mechanistic model of CDK4/6 regulation by cell cycle Inhibitors and Promoters (CIP) that couples estrogen and JNK signaling with cell cycle progression to measure the mechanisms driving cell cycle activation in a series of isogenic cell lines sensitive and resistant to CDK4/6 and endocrine inhibitors and in patient tumor cells. This analysis will reveal how distinct signaling pathways contribute to cell cycle reactivation during estrogen, CDK4/6 and JNK inhibition treatments and provide signatures of each resistant mechanism across cell types, over time and between systems. Aim 2 leverages our collection of patient tumors from the FELINE clinical trial to discover the intracellular and intratumoral resistance mechanisms driving proliferation. Fundamental resistance mechanisms will be measured in over ~300,000 patient cells from 360 tumor samples using single cell RNA sequencing data already in hand to identify core intracellular signaling states that act alone or in concert to drive proliferation. Next, the population of cells within each tumor will be analyzed to quantify intratumoral heterogeneity and how resistant populations differ in growing or shrinking tumors during drug treatment. Applying CIP to project proliferation across patient tumor cells will allow prediction of inhibitor strategies that most effectively block intracellular and intratumoral proliferation. Lastly, Aim 3 will apply a series of JNK pathway drugs with clinical potential to design and test treatment strategies that maintain durable inhibition of proliferation in ER+ cancer cells. Iterative feedback between mathematical models and patient/experimental data serves to provide a deep understanding of cell cycle regulation and mechanisms of dysregulation leading to resistance. Together, these experiments will reveal the balance between estrogen and alternative mediated JNK signaling, and their roles in resistance and provide a guide for therapeutic regimes with more durable control of cancer cell proliferation.

摘要联合细胞周期蛋白依赖性激酶（CDK）抑制剂与内分泌治疗可改善转移性乳腺癌的预后雌激素受体阳性（ER+）、HER 2阴性的乳腺癌患者。然而，这种组合的价值在有可能治愈的早期患者中，我们的初步结果检查了进化使用系列肿瘤活检的单细胞转录组学分析的早期乳腺癌肿瘤的轨迹来自术前内分泌治疗单独（来曲唑）或与细胞周期联合的临床试验抑制剂ribociclib。具有加速雌激素信号丢失的耐药肿瘤显示JNK上调而那些在治疗过程中维持雌激素信号传导的人显示出CDK 4/6活化的增强作用。与ERBB 4和ERK信号上调一致。细胞周期重建证实肿瘤细胞可以在联合治疗期间重新激活，表明对增殖状态的更强选择。我们假设在早期乳腺癌中对CDK 4/6抑制抗性是由JNKMAPK驱动的通过促进CDK 6表达的途径刺激和细胞周期的再活化，或降低细胞周期抑制剂功能。在目标1中，我们将使用CDK 4/6调节的新机制模型通过细胞周期抑制剂和促进剂（CIP）将雌激素和JNK信号传导与细胞周期进程偶联在一系列敏感和耐药的等基因细胞系中测量驱动细胞周期活化的机制， CDK 4/6和内分泌抑制剂以及患者肿瘤细胞中的表达。这项分析将揭示不同的信号在雌激素、CDK 4/6和JNK抑制治疗期间，细胞周期通路有助于细胞周期再活化，不同细胞类型、不同时间和不同系统之间的每种耐药机制的特征。目标2利用我们的从FELINE临床试验中收集患者肿瘤，以发现细胞内和肿瘤内耐药性推动扩散的机制。基本的阻力机制将在超过300，000 使用已掌握的单细胞RNA测序数据从360个肿瘤样本中提取患者细胞，细胞内信号状态单独或协同作用以驱动增殖。接下来，将分析每个肿瘤，以量化肿瘤内异质性以及耐药群体在生长中的差异。或缩小肿瘤。应用CIP来预测患者肿瘤细胞的增殖将允许预测最有效地阻断细胞内和肿瘤内增殖的抑制剂策略。最后，目标3将应用一系列具有临床潜力的JNK通路药物来设计和测试治疗策略，维持对ER+癌细胞增殖的持久抑制。数学模型间的迭代反馈患者/实验数据有助于深入了解细胞周期调控和机制失调导致抗药性。总之，这些实验将揭示雌激素和替代介导的JNK信号传导，以及它们在抗性中的作用，并为治疗方案提供指导更持久地控制癌细胞增殖。